Open AccessO‐03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
Author(s) -
M. TELEN,
R. BROWN,
R. HAGAR,
M. IDOWU,
I. OSUNKWO,
T. KALFA,
F. KUYPERS,
J. GEIB,
P. SCHROEDER,
E. WU,
P. KELLY,
S. SARAF
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000872820.66998.56
Subject(s) - medicine , acute chest syndrome , adverse effect , discontinuation , pharmacodynamics , deep vein , cohort , gastroenterology , thrombosis , disease , sickle cell anemia , pharmacokinetics